US EditionMRKR FY2028 EPS Reduced by Brookline Capital Management
Summary by reporter.am
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
MRKR FY2028 EPS Reduced by Brookline Capital Management
Marker Therapeutics, Inc. (NASDAQ:MRKR – Free Report) – Brookline Capital Management cut their FY2028 earnings per share estimates for Marker Therapeutics in a report issued on Thursday, May 15th. Brookline Capital Management analyst L. Cann now anticipates that the company will earn $2.33 per share for the year, down from their previous forecast of $2.42. […]
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
